Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 10.
doi: 10.1111/den.70033. Online ahead of print.

Clinical Outcomes and Prognostic Factors in Patients Undergoing Salvage Endoscopic Therapy for cT1N0M0 Local Failure After Chemoradiotherapy for Esophageal Cancer: A Multicenter Retrospective Study

Keiichiro Nakajo  1 , Tatsunori Minamide  2 , Hiroki Yamashita  1 , Atsushi Inaba  1 , Hironori Sunakawa  1 , Tomohiro Kadota  1 , Kensuke Shinmura  1 , Hiroyuki Ono  2 , Tomonori Yano  1
Affiliations

Clinical Outcomes and Prognostic Factors in Patients Undergoing Salvage Endoscopic Therapy for cT1N0M0 Local Failure After Chemoradiotherapy for Esophageal Cancer: A Multicenter Retrospective Study

Keiichiro Nakajo et al. Dig Endosc. .

Abstract

Objectives: Salvage endoscopic therapy is increasingly recommended for localized, superficial failure at the primary site after chemoradiotherapy for esophageal squamous cell carcinoma. This multicenter retrospective study aimed to evaluate the clinical outcomes and prognostic factors associated with overall survival in patients who underwent salvage endoscopic therapy for cT1N0M0 local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma.

Methods: We retrospectively analyzed patients with cT1N0M0 local failure after chemoradiotherapy or radiotherapy who underwent endoscopic resection or photodynamic therapy using talaporfin sodium at two Japanese institutions between 2012 and 2021. Clinical outcomes and prognostic factors for overall survival were assessed using multivariate analysis.

Results: Complete resection was achieved in 63 of 84 patients (75%) who underwent endoscopic resection, and a local complete response was achieved in 50 of 81 patients (62%) who underwent photodynamic therapy. During a median follow-up of 34 months (range, 2-109 months), 3-year overall survival, disease-specific survival, local recurrence-free survival, and esophagectomy-free survival rates were 79%, 88%, 54%, and 79%, respectively. A high Charlson Comorbidity Index (≥ 3; hazard ratio: 3.3) was significantly associated with poor overall survival (3-year overall survival rate: 64%), although the 3-year disease-specific survival in this group remained high at 94%.

Conclusions: We clarified the clinical outcomes and prognosis of salvage endoscopic therapy for cT1 local failure. The Charlson Comorbidity Index may serve as a useful prognostic factor to aid in clinical decision-making.

Keywords: chemoradiotherapy; endoscopic mucosal resection; esophageal squamous cell carcinoma; photodynamic therapy; salvage endoscopic resection.

PubMed Disclaimer

References

    1. A. Ohtsu, “Chemoradiotherapy for Esophageal Cancer: Current Status and Perspectives,” International Journal of Clinical Oncology 9 (2004): 444–450.
    1. R. Ishihara, S. Yamamoto, H. Iishi, et al., “Factors Predictive of Tumor Recurrence and Survival After Initial Complete Response of Esophageal Squamous Cell Carcinoma to Definitive Chemoradiotherapy,” International Journal of Radiation Oncology, Biology, Physics 76 (2010): 123–129.
    1. A. Herskovic, K. Martz, M. Al‐Sarraf, et al., “Combined Chemotherapy and Radiotherapy Compared With Radiotherapy Alone in Patients With Cancer of the Esophagus,” New England Journal of Medicine 326 (1992): 1593–1598.
    1. A. Suzuki, L. Xiao, Y. Hayashi, et al., “Nomograms for Prognostication of Outcome in Patients With Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy,” Oncology 82 (2012): 108–113.
    1. K. Kato, K. Muro, K. Minashi, et al., “Phase II Study of Chemoradiotherapy With 5‐Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906),” International Journal of Radiation Oncology, Biology, Physics 81 (2011): 684–690.

LinkOut - more resources